Leber hereditary optic neuropathy in Slovenia: quality of life and costs from patient perspective.


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
30 Aug 2024
Historique:
received: 30 05 2024
accepted: 19 08 2024
medline: 1 9 2024
pubmed: 1 9 2024
entrez: 30 8 2024
Statut: epublish

Résumé

Leber hereditary optic neuropathy (LHON) is the most commonly diagnosed mitochondrial disorder, resulting in colour vision abnormalities and rapid but painless deterioration of central vision. While numerous studies have assessed the impact of LHON on the quality of life (QoL) of LHON patients, the financial impact of the disease remains unexplored. This study attempts to calculate both the direct non-medical costs and the indirect costs associated with productivity losses experienced by people with LHON and their unpaid caregivers in Slovenia, in addition to assessing their QoL. Due to the rarity of the disease, the study involved a small sample size, which is important to note for interpreting the results. The analysis was conducted on nine adult participants diagnosed with LHON, representing one-third of the total number of known Slovenian patients with this condition. To thoroughly assess the economic and social impact of LHON, tailored questionnaires were designed to collect information on demographics, socioeconomic status, LHON severity, and associated non-medical and indirect costs. The mean age of the study participants was 48.8 years (SD 13.3; n = 9). The annual productivity loss attributable to LHON, taking both absenteeism and relative presenteeism into account, was calculated to be EUR 11,608 per person affected. The mean VFQ-25 score, a measure of vision-related quality of life, for adult LHON patients was 30.4 (SD 12.9). The findings highlight the significant economic and social burden of LHON on patients and their families. Ensuring prompt, accurate diagnosis, access to treatment, financial support, and psychological counselling and services are critical to helping individuals cope with and mitigate the profound challenges of vision loss and living with LHON.

Identifiants

pubmed: 39215330
doi: 10.1186/s13023-024-03329-0
pii: 10.1186/s13023-024-03329-0
pmc: PMC11365147
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

318

Informations de copyright

© 2024. The Author(s).

Références

Front Neurol. 2021 May 26;12:651639
pubmed: 34122299
J Med Genet. 1994 Apr;31(4):280-6
pubmed: 8071952
Clin Ophthalmol. 2021 Jul 01;15:2855-2866
pubmed: 34234408
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3112-5
pubmed: 19255150
Graefes Arch Clin Exp Ophthalmol. 2019 Dec;257(12):2751-2757
pubmed: 31482278
Life (Basel). 2023 Sep 30;13(10):
pubmed: 37895381
Eur J Hum Genet. 2007 Oct;15(10):1079-89
pubmed: 17406640
J Med Genet. 2009 Mar;46(3):145-58
pubmed: 19001017
Eur J Ophthalmol. 2012 May-Jun;22(3):461-5
pubmed: 21928272
Am J Hum Genet. 2003 Feb;72(2):333-9
pubmed: 12518276
J Neuroophthalmol. 2017 Dec;37(4):371-381
pubmed: 28991104
Orphanet J Rare Dis. 2022 Apr 12;17(1):163
pubmed: 35414039
Brain. 2011 Sep;134(Pt 9):2677-86
pubmed: 21788663
Arch Ophthalmol. 2001 Jul;119(7):1050-8
pubmed: 11448327
Clin Ophthalmol. 2017 Feb 22;11:417-427
pubmed: 28260855
Ann Neurol. 2015 May;77(5):753-9
pubmed: 25652200
J Clin Invest. 2021 Mar 15;131(6):
pubmed: 33465056
J Neuroophthalmol. 2019 Mar;39(1):56-59
pubmed: 29554000
Clin Ophthalmol. 2020 Mar 05;14:707-719
pubmed: 32184557
J Occup Environ Med. 2003 Feb;45(2):156-74
pubmed: 12625231
Front Neurol. 2022 Oct 28;13:1003046
pubmed: 36388184
Science. 1988 Dec 9;242(4884):1427-30
pubmed: 3201231
J Neuroophthalmol. 2020 Dec;40(4):558-565
pubmed: 32991388
J Med Genet. 2002 Mar;39(3):162-9
pubmed: 11897814

Auteurs

Marko Hawlina (M)

Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Lea Kovač (L)

Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Katarína Breciková (K)

CEEOR s.r.o., Prague, Czechia. katarina.brecikova@ceeor.com.

Jan Žigmond (J)

Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University Prague, Kladno, Czechia.

Vladimír Rogalewicz (V)

Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University Prague, Kladno, Czechia.

Aleš Tichopád (A)

Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University Prague, Kladno, Czechia.

Martin Višňanský (M)

Department of Pharmacy and Social Pharmacy, University of Veterinary Medicine and Pharmacy Košice, Košice, Slovakia.
Department of Public Economics, Faculty of Economics and Administration, Masaryk University Brno, Brno, Czechia.

Ivana Šarkanová (I)

CEEOR s.r.o., Prague, Czechia.
Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University Prague, Kladno, Czechia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH